Advertisement

Journal of Neuro-Oncology

, Volume 67, Issue 1–2, pp 177–188 | Cite as

The Combination of Adenoviral HSV TK Gene Therapy and Radiation is Effective in Athymic Mouse Glioblastoma Xenografts without Increasing Toxic Side Effects

  • Ulf Nestler
  • Hiroaki Wakimoto
  • Fernando Siller-Lopez
  • Laura K. Aguilar
  • Arnab Chakravarti
  • Alona Muzikansky
  • Anat Stemmer-Rachamimov
  • E. Antonio Chiocca
  • Estuardo Aguilar-Cordova
  • Fred H. Hochberg
Article

Abstract

Object: In mouse models of prostate and breast cancer therapeutic effects are enhanced when adenoviral HSV TK gene therapy is combined with ionizing radiation. In the present study, we adopted this approach for the treatment of human glioblastoma xenografts in an athymic mouse model and assessed treatment results as well as toxic side effects.

Methods: About 72 nude mice received intracerebral inoculations of 2 × 105 U87ΔEGFR cells. On day 7 after tumor implantation the study population was randomized into six treatment arms: (1) intratumoral buffer inoculation on day 7, (2) intratumoral adenoviral vector injection (2 × 109 vp) on day 7, (3) single dose radiation (2.1 Gy) on day 9, (4) adenoviral injection + radiation, (5) adenoviral injection + ganciclovir (GCV) (20 ug/g twice daily from day 8 to 17), (6) adenoviral injection + GCV + radiation. On day 21 half of the animals were sacrificed for histological evaluation of the brain tumors, the other half was assessed for survival.

Results: This study showed significantly prolonged median survival time of 5 days for the GCV treated groups. The addition of radiation decreased the frequency of neurological symptoms and delayed the onset of deficits without altering the expression of thymidine kinase in the tumor cells.

Conclusions: We conclude that adenoviral HSV TK gene therapy in combination with adjuvant radiotherapy does not generate increased toxic side effects in glioblastoma treatment. The prolonged survival time of animals receiving gene therapy and the reduced occurrence of neurological symptoms in irradiated mice constitute promising features of the combined treatment.

ganciclovir human glioblastoma single dose radiation spheroid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kaaijk P, Troost D, Sminia P, Hulshof MCCM, van der Kracht AHW, Leenstra S, Bosch DA: Hypofractionated radiation induces a decrease in cell proliferation but no histological damage to organotypic multicellular spheroids of human glioblastoma. Eur J Cancer 33(4): 645–651, 1997CrossRefPubMedGoogle Scholar
  2. 2.
    Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, Hirakawa K: Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 77(2): 373–380, 1996CrossRefPubMedGoogle Scholar
  3. 3.
    Goodman JC, Trask TW, Chen S-H, Woo SLC, Grossman RG, Carey KD, Hubbard GB, Carrier DA, Rajagopalan S, Aguilar-Cordova E, Shine HD: Adenoviralmediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies. Hum Gene Ther 7: 1241–1250, 1996PubMedGoogle Scholar
  4. 4.
    Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, Arafat W, Hughes JV, Siegal GP, Curiel DT: Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2(5): 524–530, 2000CrossRefPubMedGoogle Scholar
  5. 5.
    Eck SL, Alavi JB, Judy K, Phillips P, Alavi A, Hackney D, Cross P, Hughes J, Gao GP, Wilson JM, Propert K: Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVIFN-β): a phase I trial. Hum Gene Ther 12: 97–113, 2001PubMedGoogle Scholar
  6. 6.
    Nestler U, Heinkelein M, Lücke M, Meixensberger J, Scheurlen W, Kretschmer A, Rethwilm A: Foamy virus vectors for suicide gene therapy. Gene Ther 4(11): 1270–1277, 1997CrossRefPubMedGoogle Scholar
  7. 7.
    Packer RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, LaFond D, McComb JG, Cogen PH, Vezina G, Kapeala LP: Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector–producer cells followed by intravenous ganciclovir administration. J Neurosurg 92: 249–254, 2000PubMedGoogle Scholar
  8. 8.
    Aghi M, Hochberg F, Breakefield XO: Prodrug activation enzymes in cancer gene therapy. J Gene Med 2: 148–164, 2000CrossRefPubMedGoogle Scholar
  9. 9.
    Little JB: Delayed initiation of DNA synthesis in irradiated human diploid cells. Nature 218: 1064–1065, 1968PubMedGoogle Scholar
  10. 10.
    Leskov KS, Criswell T, Antonio S, Li J, Yang CR, Kinsella TJ, Boothman DA When X-ray-inducible proteins meet DNA double strand break repair Semin Radiat Oncol 11(4): 352–372, 2001CrossRefPubMedGoogle Scholar
  11. 11.
    Vlachaki MT, Chhikara M, Aguilar L, Zhu X, Chiu KJ, Woo S, Teh BS, Thompson TC, Butler EB, Aguilar-Cordova E: Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys 51(4): 1008–1017, 2001CrossRefPubMedGoogle Scholar
  12. 12.
    Chhikara M, Huang H, Vlachaki MT, Zhu X, Teh B, Chiu KJ, Woo S, Berner B, O'Brian Smith E, Oberg KC, Aguilar LK, Thompson TC, Butler EB, Aguilar-Cordova E: Enhanced therapeutic effect of HSV-TK+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 3: 536–542, 2001CrossRefPubMedGoogle Scholar
  13. 13.
    Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, Harsh GR IV, Louis DN, Bartus RT, Hochberg FH, Chiocca EA: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Med 5(8): 881–887, 1999PubMedGoogle Scholar
  14. 14.
    Rojas-Martinez A, Wyde PR, Montgomery CA, Chen SH, Woo SLC, Aguilar-Cordova E: Distribution, persistency, toxicity, and lack of replication of an E1A-deficient adenoviral vector after intracardiac delivery in the cotton rat. Cancer Gene Ther 5(6): 365–370, 1998PubMedGoogle Scholar
  15. 15.
    Groenvik C, Capala J, Carlsson J: The non-variation in radiosensitivity of different proliferative states of human glioma cells. Anticancer Res 16(1): 25–31, 1996Google Scholar
  16. 16.
    Zoelzer F, Streffer C: Quiescence in S-phase and G1 arrest induced by irradiation and/or hyperthermia in six human tumour cell lines of different p53 status. Int J Radiat Biol 76(5): 717–725, 2000Google Scholar
  17. 17.
    Sutherland RM: Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240: 177–184, 1988PubMedGoogle Scholar
  18. 18.
    Valter MM, Hügel A, Huang HJS, Cavenee WK, Wiestler OD, Pietsch T, Wernert N: Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/Vascular Endothelial Growth Factor receptor-1 synthesis and neoangiogenesis. Cancer Res 59: 5608–5614, 1999PubMedGoogle Scholar
  19. 19.
    Kleihues P, Cavenee WK (eds): Tumours of the Nervous System. Pathology & Genetics, IARC Press, Lyon, 2000Google Scholar
  20. 20.
    Raza SM, Lang FF, Aggarwal BB, Fuller GN, Wildrick DM, Sawaya R: Necrosis and glioblastoma: a friend or a foe? A review and hypothesis. Neurosurgery 51(1): 2–12, 2002CrossRefPubMedGoogle Scholar
  21. 21.
    Freyer JP: Role of necrosis in regulating the growth saturation of multicellular spheroids. Cancer Res 48(9): 2432–2439, 1988PubMedGoogle Scholar
  22. 22.
    Nofech-Mozes Y, Yuhas Y, Kaminsky E, Weizman A, Ashkenazi S: Induction of mRNA for tumor necrosis factor-alpha and interleukin-1 beta in mice brain, spleen and liver in an animal model of Shigella-related seizures. IsrMed Assoc J 2000 2(2): 86–90, 2000Google Scholar
  23. 23.
    Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SLC: Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 91: 3054–3057, 1994PubMedGoogle Scholar
  24. 24.
    Ram Z, Walbridge S, Shawker T, Culver KW, Blaese RM, Oldfield EH: The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 81: 256–260, 1994PubMedGoogle Scholar
  25. 25.
    Valerie K, Hawkins W, Farnsworth J, Schmidt-Ullrich R, Lin PS, Amir C, Feden J: Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir. Cancer Gene Ther 8(1): 3–8, 2001PubMedGoogle Scholar
  26. 26.
    Taghian A, Budach W, Zietman A, Freeman J, Gioioso D, Suit HD: Quantitative comparison between the transplantability of human and murine tumors into the brain of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. Cancer Res 53: 5018–5021, 1993PubMedGoogle Scholar
  27. 27.
    Shine HD, Wyde PR, Aguilar-Cordova E, Chen SH, Woo SLC, Grossman RG, Goodman JC: Neurotoxicity of intracerebral injection of a replication-defective adenoviral vector in a semipermissive species (cotton rat). Gene Ther 4: 275–279, 1997CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Ulf Nestler
    • 1
    • 4
  • Hiroaki Wakimoto
    • 1
    • 2
  • Fernando Siller-Lopez
    • 7
  • Laura K. Aguilar
    • 7
  • Arnab Chakravarti
    • 4
  • Alona Muzikansky
    • 6
  • Anat Stemmer-Rachamimov
    • 5
  • E. Antonio Chiocca
    • 1
    • 2
  • Estuardo Aguilar-Cordova
    • 7
    • 8
  • Fred H. Hochberg
    • 3
  1. 1.Molecular Neuro-Oncology LaboratoryMassachusetts General Hospital EastCharlestownUSA
  2. 2.Department of NeurosurgeryMassachusetts General Hospital EastCharlestownUSA
  3. 3.Department of NeurologyMassachusetts General Hospital EastCharlestownUSA
  4. 4.Department of Radiation OncologyMassachusetts General Hospital EastCharlestownUSA
  5. 5.Laboratory of NeuropathologyMassachusetts General Hospital EastCharlestownUSA
  6. 6.Biostatistics CenterMassachusetts General HospitalBostonUSA
  7. 7.Harvard Gene Therapy InitiativeHarvard Medical SchoolBostonUSA
  8. 8.Advantagene IncSan DiegoUSA

Personalised recommendations